Thermo Fisher raised its revenue forecast after Q2 sales beat expectations, supported by stronger biotech/pharma spending and a rebound in laboratory instrument demand. The company’s updated outlook reflects demand strength rather than one-off effects, driving shares higher on the news.
Thermo Fisher raised its revenue forecast after Q2 sales beat expectations, supported by stronger biotech/pharma spending and a rebound in laboratory instrument demand. The company’s updated outlook reflects demand strength rather than one-off effects, driving shares higher on the news.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
